Modulating Movement Intention Via Cortical Stimulation

Launched by NYU LANGONE HEALTH · Jul 25, 2017

Keywords

ClinConnect Summary

This clinical trial, titled "Modulating Movement Intention Via Cortical Stimulation," aims to better understand how people intend to move and how those intentions can be influenced. Researchers are particularly interested in conditions like seizures and psychogenic movement disorder (PMD), which can cause involuntary movements. The study is currently seeking participants aged 6 to 74, including both healthy individuals and patients diagnosed with PMD or psychogenic non-epileptic seizures (PNES). To join, participants must be fluent in English and, for patients, have a confirmed diagnosis of PMD or PNES without needing any immediate treatment changes for several months.

If you or a family member are considering participating in this trial, you can expect to take part in various non-invasive tests that will help researchers gather important information about movement intention. However, there are specific eligibility criteria to ensure safety and reliable results. For instance, individuals with a history of significant neurological disorders, certain psychiatric conditions, or metal devices in the head may not be eligible. This study could pave the way for future treatments that help manage symptoms of PMD and improve the quality of life for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (Healthy Controls)
• • Fluent in English
• (Patients with PMD or PNES):
• • Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders.
• • Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening
• Exclusion Criteria:
• • Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI
• • Chronic or progressive medical condition
• • Any history of traumatic brain injury or significant head trauma
• • Currently meets criteria for substance abuse or dependence
• • History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation
• • Pregnancy
• • Metal or devices in the head, including neurostimulators or metal foreign bodies
• • Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
• • Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).
• • Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009
• • Current diagnosis of any inflammatory or autoimmune disorder within last 6 months
• • PMD and PNES Patients
• • Any history of traumatic brain injury or significant head trauma
• • Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;
• • Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);
• • Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months
• • Metal or devices in the head, including neurostimulators or metal foreign bodies
• • Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009;
• • Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;
• • Recurrent visual hallucinations, within the past 6 months;
• • History of significant uncontrollable movements of the head;
• • Any clinically significant abnormality on vital signs